Borja Ballarín-González

Title: Borja Ballarín-González: Innovator in Amylin Receptor Potency

Introduction

Borja Ballarín-González is a notable inventor based in Høsholm, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target amylin receptors. His work is crucial in addressing medical conditions such as obesity, NASH, and diabetes.

Latest Patents

Borja holds a patent for "HAManalogues with improved amylin receptor (hAMY3R) potency." This invention relates to hAManalogues that exhibit enhanced potency for the amylin receptor (hAMY3R-EC≤250 pM). The hAManalogues are primarily based on the sequence of the human adrenomedullin fragment hAM. They are selective agonists for the amylin receptor, maintaining good physical stability and offering potential therapeutic applications.

Career Highlights

Borja is associated with Gubra A/S, a company focused on innovative solutions in the field of metabolic diseases. His work at Gubra has positioned him as a key player in the development of new therapeutic agents. With a patent portfolio that includes 1 patent, he continues to push the boundaries of research in his field.

Collaborations

Borja collaborates with talented individuals such as Jens Christian Frøslev Nielsen and Kristoffer Tobias Gustav Rigbolt. These partnerships enhance the innovative capacity of his projects and contribute to the advancement of their shared goals.

Conclusion

Borja Ballarín-González exemplifies the spirit of innovation in the pharmaceutical industry. His work on amylin receptor potency has the potential to make a significant impact on the treatment of various medical conditions.